SG11201901928SA - Mucoadhesive microorganism - Google Patents

Mucoadhesive microorganism

Info

Publication number
SG11201901928SA
SG11201901928SA SG11201901928SA SG11201901928SA SG11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA
Authority
SG
Singapore
Prior art keywords
international
bacteria
microorganism
microorganisms
pct
Prior art date
Application number
SG11201901928SA
Inventor
Lothar Steidler
Klaas Vandenbroucke
Original Assignee
Intrexon Actobiotics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics N V filed Critical Intrexon Actobiotics N V
Publication of SG11201901928SA publication Critical patent/SG11201901928SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Abstract

ORIBseRI Eco III BaeG I ApaLl Sfol Narl Kasl Fspl EcoRl Avail BtgZ I Scal Acul Acc651 Kpnl Agel Bsu361 2000 cmbA SSusp45 htff3 6000 1000 pAGX2005 (AGX No 3156) — 5000 6843 bps 4000 3000 / \ Em PthyA thyA 3' Hpal BspHI Afl III SgrDI (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 March 2018 (22.03.2018) WI P0 I PCT omit IIl °nolo III um Oil Oil °mono X10 mmIE (10) International Publication Number WO 2018/051223 A4 BamHI Eci I Mscl (51) International Patent Classification: C07K 14/705 (2006.01) (21) International Application Number: PCT/IB2017/055470 (22) International Filing Date: 11 September 2017 (11.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/394,024 13 September 2016 (13.09.2016) US (71) Applicant: INTREXON ACTOBIOTICS N.V. [BE/BE]; Technologiepark 4, B-9052 Zwijnaarde (BE). (72) Inventors: STEIDLER, Lothar; Bokslaarstraat 41, B-9160 Lokeren (BE). VANDENBROUCKE, Klaas; Bachtenboslaan 5, B-9840 De Pinte (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (54) Title: MUCOADHESIVE MICROORGANISM Xbal Sbfl Sapl Sphl Taul thyA 5' Clal BseYI Gsal Pmll SnaBI FIG. 1 (57) : The present disclosure provides genetically modified microorganisms bacteria or yeast) with enhanced mucin- (e.g., binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms bacteria). (e.g., [Continued on next page] BsrG I Drdl Blpl WO 2018/051223 A4 MIDEDIMOMOIDEIREEMOOMMEMOHHOMOOMEEN UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with amended claims (Art. 19(1)) with sequence listing part of description (Rule 5.2(a)) Date of publication of the amended claims: 03 May 2018 (03.05.2018)
SG11201901928SA 2016-09-13 2017-09-11 Mucoadhesive microorganism SG11201901928SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662394024P 2016-09-13 2016-09-13
PCT/IB2017/055470 WO2018051223A1 (en) 2016-09-13 2017-09-11 Mucoadhesive microorganism

Publications (1)

Publication Number Publication Date
SG11201901928SA true SG11201901928SA (en) 2019-04-29

Family

ID=60190901

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901928SA SG11201901928SA (en) 2016-09-13 2017-09-11 Mucoadhesive microorganism

Country Status (11)

Country Link
US (3) US10808014B2 (en)
EP (1) EP3512872A1 (en)
JP (2) JP7022743B2 (en)
KR (2) KR102469701B1 (en)
CN (1) CN109983028B (en)
AU (2) AU2017328129B2 (en)
CA (1) CA3035488A1 (en)
IL (1) IL265177A (en)
RU (2) RU2021135949A (en)
SG (1) SG11201901928SA (en)
WO (1) WO2018051223A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111491657A (en) 2017-10-20 2020-08-04 哈佛学院院长及董事 Artificial secretory peptides for heterologous protein production
CN110129220B (en) * 2019-04-30 2021-06-22 石河子大学 Lactobacillus bulgaricus BSTS6-4 and application thereof
CA3152665A1 (en) * 2019-08-27 2021-03-04 Tonix Pharma Limited Modified tff2 polypeptides
CA3156035A1 (en) * 2019-09-27 2021-04-01 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
WO2021158376A1 (en) * 2020-02-06 2021-08-12 Codexis, Inc. Mucin-binding fusion proteins
CN111690666B (en) * 2020-07-30 2023-05-05 江苏食品药品职业技术学院 Recombinant thaumatin II structural gene, expression vector, method for producing sweet protein and application
KR102231437B1 (en) * 2020-09-21 2021-03-24 주식회사 보삼바이오산업 Manufacturing method of composition for the prevention or treatment of highly pathogenic avian influenza virus and composition for the prevention or treatment of highly pathogenic avian influenza virus using the same
CN112195210B (en) * 2020-10-24 2022-01-04 上海加新生物科技有限公司 Production method of hyaluronic acid
CN112708577B (en) * 2020-12-31 2022-04-05 扬州大学 Lactobacillus fermentum DALI02 with high intestinal adhesion and immunoregulation function and application thereof
WO2022174226A1 (en) * 2021-02-09 2022-08-18 University Of Massachusetts Intracellular delivery of therapeutic proteins designed to invade and autonomously lyse and methods of use thereof
CN113684201A (en) * 2021-08-27 2021-11-23 日照市畜牧兽医管理服务中心 Breeding method for screening intestinal tract colonization probiotics based on Caco-2 cell high-efficiency mutagenesis
CN114377117B (en) * 2021-12-06 2023-11-10 中国医学科学院医学生物学研究所 Oral type 1diabetes vaccine and preparation method thereof
CN115197885B (en) * 2022-09-13 2022-12-09 中国农业科学院北京畜牧兽医研究所 Lactococcus garvieae LGM15, microbial inoculum and application

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB227835A (en) 1924-01-15 1925-04-09 Harry Odell Improvements in feeding mechanism for embossing and other printing presses
US4919918A (en) 1988-03-14 1990-04-24 Spectrum Consumer Products Co., Inc. Non-alcoholic mouthwash
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9126306D0 (en) 1991-12-11 1992-02-12 Unilever Plc Mouthwash compositions
CA2130453A1 (en) 1992-02-27 1993-09-02 Richard W. F. Le Page Heterologous gene expression in lactococcus, and the expression products threrefrom
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5700782A (en) 1993-05-28 1997-12-23 Abbott Laboratories Enteral nutritional product
AU2149495A (en) 1995-04-11 1996-10-30 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
AU1533697A (en) 1996-01-24 1997-08-20 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en) 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
WO1998011866A1 (en) 1996-09-18 1998-03-26 Erling Johansen Mouthwash comprising calcium and phosphate ions in supersaturated solution
US5869118A (en) 1996-11-13 1999-02-09 Abbott Laboratories Gellan gum to improve physical stability of liquid nutritional products
US6171611B1 (en) 1997-11-12 2001-01-09 Dante J. Picciano Iodine-containing nasal moisturizing saline and mouthwash solutions
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
CN100358509C (en) 1998-09-28 2008-01-02 沃纳-兰伯特公司 Enteric and colonic delivery using HPMC capsules
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
DK1194554T3 (en) 1999-07-05 2007-01-29 Vlaams Interuniv Inst Biotech Administration of tricyclic peptides
WO2002090551A2 (en) 2001-05-03 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
WO2002102403A1 (en) * 2001-06-14 2002-12-27 Novo Nordisk A/S Mucosal repair by tff dimer peptides
US20030219402A1 (en) 2002-02-14 2003-11-27 Rutter William J. Chimeric molecules for cleavage in a treated host
US20040131567A1 (en) 2002-07-08 2004-07-08 Wilkins Joe S. Antibacterial topical formulations
JP2007530034A (en) 2004-03-23 2007-11-01 エヌ.ブイ.・ヌートリシア Novel mannose-specific adhesins and their use
WO2006018446A2 (en) 2004-08-20 2006-02-23 Actogenix Nv Method to improve lactococcus preservation
CA2925307C (en) 2005-08-30 2019-12-03 Intrexon Actobiotics Nv Novel treatment of chronic enterocolitis
CA2631598C (en) 2005-11-29 2017-06-27 Actogenix Nv Induction of mucosal tolerance to antigens
US20090311249A1 (en) 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
ES2595729T3 (en) * 2007-01-12 2017-01-03 Intrexon Actobiotics Nv Lactococcus promoters and their uses
EP3351268B1 (en) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
US20100178273A1 (en) * 2007-06-20 2010-07-15 Actogenix Nv Corporation Methods and compositions for treating mucositis
AU2010209584C1 (en) * 2009-02-02 2016-09-08 Chr. Hansen A/S Lactobacillus rhamnosus pilus polypeptides and methods for producing them
CN102414310B (en) 2009-04-30 2015-05-06 阿克图杰尼斯公司 Cryoprotectants for freeze drying of lactic acid bacteria
WO2012164083A1 (en) 2011-06-01 2012-12-06 Actogenix N.V. Polycistronic expression system for bacteria
DK2717712T3 (en) * 2011-06-09 2019-12-16 Novozymes As Fusion of bioactive molecules
EP2758512B1 (en) 2011-09-23 2018-05-09 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
WO2013041673A1 (en) 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
EP2914274A4 (en) * 2012-11-01 2016-07-20 Sydney Children S Hospital Network Randwick And Westmead Genetically-modified probiotic for treatment of phenylketonuria
WO2016124239A1 (en) * 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
US10905727B2 (en) 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
WO2018042390A1 (en) 2016-09-02 2018-03-08 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing il-10 and insulin

Also Published As

Publication number Publication date
AU2021202595A1 (en) 2021-05-27
RU2762940C2 (en) 2021-12-24
CN109983028A (en) 2019-07-05
US11384123B2 (en) 2022-07-12
JP2022084579A (en) 2022-06-07
US20210070815A1 (en) 2021-03-11
KR20220005641A (en) 2022-01-13
US10808014B2 (en) 2020-10-20
CA3035488A1 (en) 2018-03-22
JP7439148B2 (en) 2024-02-27
EP3512872A1 (en) 2019-07-24
IL265177A (en) 2019-05-30
CN109983028B (en) 2023-10-20
KR102469701B1 (en) 2022-11-22
RU2021135949A (en) 2022-04-14
KR20190056387A (en) 2019-05-24
RU2019108553A3 (en) 2020-12-15
US20190194267A1 (en) 2019-06-27
JP7022743B2 (en) 2022-02-18
KR102348734B1 (en) 2022-01-07
AU2017328129B2 (en) 2021-01-28
RU2019108553A (en) 2020-10-15
AU2021202595B2 (en) 2022-02-17
US20230013523A1 (en) 2023-01-19
JP2019530446A (en) 2019-10-24
WO2018051223A4 (en) 2018-05-03
WO2018051223A1 (en) 2018-03-22
AU2017328129A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
SG11201901928SA (en) Mucoadhesive microorganism
SG11201906341XA (en) Improved serum albumin binders
SG11201906264YA (en) Improved serum albumin binders
SG11201806398YA (en) Optimized factor viii genes
SG11201803169WA (en) Cellulase variants and polynucleotides encoding same
SG11201806988UA (en) Improved differentiation method
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201806758VA (en) Vcn enhancer compositions and methods of using the same
SG11201808751SA (en) T cell receptors
SG11201810509PA (en) Anti-pd-l1 antibodies
SG11201909203WA (en) Tissue selective transgene expression
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201906213UA (en) Modulating expression of polypeptides via new gene switch expression systems
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201909331UA (en) Antigen-specific immune effector cells
SG11201907769XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11201911572YA (en) Adenoviral vectors
SG11201805680SA (en) Methods and compositions for the treatment of neurologic disease
SG11201906359SA (en) Compositions and methods for maturation of oocytes in vitro
SG11201810040WA (en) Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
SG11201809473QA (en) Humanized anti-basigin antibodies and the use thereof
SG11201805494WA (en) Mutated von willebrand factor